CLINICAL_TRIALS
withdrawal
· 2015-09-01
Clinical Trial Update: Study of LJP 394 (Abetimus Sodium) in Lupus Patients [Phase 2]
Summary
A Phase 2 study of LJP 394 (Abetimus Sodium) in patients with systemic lupus erythematosus has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: La Jolla Pharmaceutical Company | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: WITHDRAWN